Helicobacter Pylori Eradication Strategies and Gastric Cancer Prevention
This community focuses on the clinical treatment of Helicobacter pylori infection, specifically comparing antibiotic regimens and acid-suppressing agents to eradicate the bacterium and prevent the development of gastric cancer.
The research is dominated by randomized controlled trials and systematic meta-analyses evaluating the efficacy and safety of specific therapeutic protocols. Recurring subjects include bismuth-containing quadruple therapies, dual therapies, and the comparison of traditional proton pump inhibitors against newer potassium-competitive acid blockers. A significant portion of the work addresses the rising challenge of antibiotic resistance and the long-term impact of eradication on gastric carcinogenesis. The literature also frequently examines the role of probiotics in managing treatment side effects and the specific management of pediatric and adult populations across different geographic regions.
The largest share of the community's output is found in bismuth research, accounting for 3.5% of all bismuth-related papers tracked, with 3,176 papers in this group. Nitrogen and potassium research also feature prominently, reflecting the chemical composition of the acid-suppressing drugs and antibiotics used in these regimens.
There are 10,255 papers in this community, with the highest publication volumes in Gastroenterology, Gut, and Helicobacter.
Recent work continues to refine treatment guidelines, including the Taipei Global Consensus II and updated Japanese guidelines, while new clinical trials test the efficacy of tegoprazan-based dual and triple therapies as alternatives to standard regimens.